finance

Health Tech By Erin Brodwin

Haven, ambitious health venture backed by Amazon, to shut down

First Opinion By Bob Kocher and Bryan Roberts

Incentives and information drive health care innovation: lessons from Medicare Advantage

First Opinion By Til Schuermann and Helen Leis

We stress tested banks in 2009. We need to do the same thing now for U.S. hospital systems

Biotech By Damian Garde

How 2020 became the year of the biotech SPAC

First Opinion By Cecile Riboud

In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment

Biotech By Kate Sheridan

Months of limbo at OpenBiome put fecal matter transplants on hold across the country

Biotech By Kate Sheridan

Is Philadelphia’s biotech cluster faltering? Experts say no, even as funding dwindles

Biotech By Kate Sheridan

‘Stealth’ VC firm Aditum Bio launches its second biotech startup

Biotech By Kate Sheridan

How some biotechs are cramming multiple fundraising rounds into a single year

Biotech By Matthew Herper

Bristol Myers Squibb to buy MyoKardia for $13 billion

Health Tech By Rebecca Robbins and Erin Brodwin

What we learned about the digital pharmacy business from Hims & Hers filing to go public

Pharmalot By Ed Silverman

Not by the numbers: Former Aceto controller is charged with insider trading

Pharmalot By Ed Silverman

Novartis sells bonds tied to expanding access to medicines in poor countries

First Opinion By Alexander Borsa, Joseph Bruch, and Sarah S. Richardson

When private equity firms invest in women’s health clinics, who benefits?

Biotech By Kate Sheridan

How much is a startup worth? For biotech companies, the answer is rarely public

Something Ventured By Kate Sheridan

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

Health Tech By Andy Rosen — Boston Globe

Biofourmis raises $100 million for remote patient monitoring tools

Health Tech By Rebecca Robbins

What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings

Health Tech By Rebecca Robbins

STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic

Health Tech By Rebecca Robbins

Otsuka approved to buy bankrupt smart-pill maker Proteus’ assets, overcoming opposition from Novartis

Special Report By Rebecca Robbins and Erin Brodwin

How Teladoc won: The inside story of how well-timed bets propelled it ahead of the competition

Health Tech By Rebecca Robbins

Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech

Health Tech By Erin Brodwin

Teladoc rival MDLive is preparing to go public next year

Biotech By Kate Sheridan

4 questions for neurology startups as venture investors pour millions into the field

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed